Enhanced Nutrition for Preterm Infants
Status: | Recruiting |
---|---|
Conditions: | Women's Studies |
Therapuetic Areas: | Reproductive |
Healthy: | No |
Age Range: | Any |
Updated: | 10/13/2018 |
Start Date: | August 15, 2017 |
End Date: | July 31, 2019 |
Contact: | Mary Pat Osborne, RN |
Email: | marypat@umn.edu |
Phone: | 612-624-0581 |
Enhanced Early Nutrition for Preterm Infants to Improve Neurodevelopment and Minimize Metabolic Risk
The overall objective of the proposal is to demonstrate the feasibility of providing
increased calories and protein in the first week of life to very low birth weight (VLBW)
preterm infants.
increased calories and protein in the first week of life to very low birth weight (VLBW)
preterm infants.
Infants will be randomized to receive either standard parenteral nutrition via the neonatal
intensive care unit (NICU) protocol or enhanced parenteral nutrition via the Study protocol
during their first week of life through higher initial macronutrient provision and faster
advancement of macronutrient provision.
intensive care unit (NICU) protocol or enhanced parenteral nutrition via the Study protocol
during their first week of life through higher initial macronutrient provision and faster
advancement of macronutrient provision.
Inclusion Criteria:
- VLBW (birth weight <1500grams) preterm (gestational age (GA) at birth < 32 weeks)
infants admitted to the University of Minnesota Masonic Children's Hospital NICU, for
which written informed consent can be secured from a parent within 12 hours of birth.
Exclusion Criteria:
- Infants who are diagnosed prenatally with a clinical condition (other than
prematurity) that is known to affect growth rate, adiposity, or neurocognitive
development, who experienced severe birth asphyxia, who are enrolled in another study
affecting nutritional management, or who are likely to be transferred out of the NICU
will be excluded from participation.
We found this trial at
1
site
2450 Riverside Avenue
Minneapolis, Minnesota 55454
Minneapolis, Minnesota 55454
Principal Investigator: Sara E Ramel, MD
Phone: 612-624-0581
Click here to add this to my saved trials